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INTRODUCTION 
 
Breast cancer is the most common female neoplasm in western countries [1]  and 
bone tissue is the preferred metastatic site [2]. Overall, 65-75% of the patients with 
advanced disease will develop bone metastasis[3], with several complications as pain, 
fractures and spinal cord compression. Adequate follow up and early diagnosis will 
reduce those complications. The etherogeneity of the biology of breast cancer has 
been a major obstacle for the definition of the biological mechanisms of malignant 
spreading and organ trophism [4]. Some series in the literature report correlation 
between extracellular matrix and bone metastasis.  
The aim of our study is to evaluate the expression of molecules involved in the 
regulation or disregulation of extracellular matrix and their relationship with the risk 
of bone metastatization.  
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1. BREAST CANCER 
Breast cancer is the most common female neoplasm in developed countries: it 
represents the first cause of death for cancer in women between 40-55 years old. The 
main risk factors for breast cancer are: age at menarche, age at the first pregnancy, 
the increase of the benign proliferative disease of the breast, obesity. In 10% of the 
cases the neoplasm has some hereditary tract. Primary prevention can reduce the 
incidence of breast cancer[5]. 
 
1.1 Epidemiology 
Breast cancer is epidemiologically etherogeneous across different geographical areas. 
The higher incidence and prevalence are in North America and North Europe, where 
the female population has a relative risk 5-10 times of developing breast cancer 
comapared with Asian and african population [1]. From the eighties, in the western 
world, the diagnosis of ductal carcinoma in situ and stage I invasive ductal carcinoma 
have increased of about 3.7 percentage points/year due to prevention programs as 
mammography sreening. By the year 2000, the incidence and prevalence has 
progressively diminished by 2% yearly. This phenomeon can be due to the results of 
the Women’s Health Iniziative, an epidemiological study sowing an increase in 
inceidence of breast cancer and myocardial infarction in people assuming estro-
progestinic hormonal therapy [6]. 
On the opposite, the low prevalence of breast cancer in African and asian population 
can be due to the lesser plasmatic concentration of estro-progestinic hormones in the 
premenopausal period. However, the lifestyle modifications, such as higher caloric 
intake, especially lipids, menarce and pregnancy age has led to an increasing in the 
incidence in breast cancer even in these populations[7-9].  
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1.1.1 Mortality 
 The mortality rate for breast cancer has declined from 1975[1], due to 
mammografic screening and the new adjuvant treatments. The mortality has 
decreased significantly in people under 50 years old (3,8 % yearly) with regard to 
people with less than 50 years old (2,2 % yearly). This reduction was more 
significant for tumors espressing both estrogen and progesteron receptors[10]. 
 
1.1.2 The Italian scenario  
In Italy there are 400000 women that are diagnosed as having breast cancer every 
year, the 20-25% of all female tumors, and 8000 die from this disease.  
The mortality rate for breast cancer has been increased until 27 every 100000 people 
and then has decreased of about 30% in the last three decades. There are screening 
programmes in Italy nowadays and the survival is one of the longest in Europe[11]. 
The 5-year survival for breast cancer has increased from 65% to 82% between 1978 
and 1994 in Italy. 
 
1.2 Pathogenesis 
The malignant trasformation is a multistep process that involves genetic and 
epigenetic mutations. The cancer cells became able to escape from antiproliferative 
and apoptotic signallings and acquire hypersensibility to proliferation stimuli. 
Genetic instability can play a role in the disregulation of cell growth[12, 13].   
The morphological and biological characteristics of breast cancer are acquired at the 
in situ stage, as well as the relapses have the same characteristics of the early stage 
disease.  
The interaction between epithelial and stomal cellss plays a role in the transition 
between in situ and ivasive carcinoma. The loss of basal membrane, the icreased 
epithelial proliferation, the loss of growth inhibition, angiogenesis and stromal 
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invasion are all acquired during tumorigenesis [14]. The loss of basal membrane and 
tissutal integrity has a further role in the malignant transformation. 
 
1.3 Biomolecular classification of breast cancer 
 
Breast cancer is a etherogeneous disease, with different biological subtypes[15]. 
The pattern analysis of the genetic espression and activity can categorize breast 
cancer in different subtypes: the variants characterized by a major or minor estrogen 
and progestinic receptor espression respectively (Luminal A and B), the forms with 
hyperespession of HER-2/neu (human epidermal growth factor receptor 2), the 
basaliod type. The distinction between ER-positive and ER-negative forms is 
relevant, due to the distinct biological behaviour and origin [16]. 
The luminal carcinoma takes origin from omonimous cells, espress the luminal 8 and 
18 cytokeratines and espress the estrogens and progestinic receptors. There is a 
further subclassification into a subtype A, more frequent, with a significative 
espression of genes correlated with estrogen receptors, low HER-2/neu espressione. 
The subtype B has a lower espression of ER-related genes, HER-2/neu espression.  
HER-2/neu positive forms are the 10-15% of all breast cancers, have a low luminal 
genic clusters espression, and usually are ER and PR negative. The basalioid subtype 
espress the cytokeratines of mammarian precursors (p-cadherins) and of mioepithelial 
cells. These are poorly differentiated forms with a bad prognosis[17].  
 
1.4 Cinical aspects 
Lesions in early stage have generally a favorable evolution; rarely there are typical 
symptoms at the diagnosis. These include mastalgia, nodulations, morfological breast 
modifications or pathological nipple secretions[18]. 
The mastodinia is the most frequent mammarian symptom (10%). The neoplastic 
breast pain is usually modest, however 11% of patints refer severe, monolateral 
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symtoms[19, 20]. The painful symptoms are typical of inflammatory carcinoma with 
skin modifications such as eczema. 
The presence of palpable nodules is the most frequent clinical sign. The breast mass 
is eviden when it reaches 1-2 cm of dimeter. The benign nodulations are frequent in 
premenopausal age. Only 10% of mammarian nodules in women under 40 years old 
are malign, while 60% of breast mass are tumors in post-menopausal women[21]. 
The clinical analysis has a positive predictive value under 73% and a negative 
predictive value of 87%[22]. The nipple secretion is a less frequent presenting 
clinical sign. The milky secretion  is a presentation of a clinical disthyroidism and has 
been never associated with malignancies. An hemorrhagic secretion is typical of 
benign disease, however can be a presentation of malignant disease rarely. The most 
common cuses of spontaneous nipple secretions are the solitary papilloma of the 
ducts, cysts and carcinomas. The latter has an incidence of 7% in women with less 
than 60 years and of 30% in older women [23]. 
Malign mammarian lesions can present with progressive nipple inversion or 
retraction. Axillary, supraclavear, mediastinic and internal mammary 
lymphoadenopaties can be associated to this clinical picture.  
 
1.5 Diagnosis and prevention 
The early diagnosis, with the use of mammography screening, is considered the most 
important chance to cure and to improve survival [24]. The mortality rate is 
dependent of the initial stage. Annual screening reduces the probability of dying of 
about 25-30% [25]. 
Bilateral mammography is the gold standard for women with 50 years old or more; 
for women 40 to 49 years old mammography is indicate only for those with an 
increased risk of breast cancer [26]. 
Screening in Italy is performed every two years in women from 50 to 69 years old. 
From 2001 this procedure has been included into the “Livelli Essenziali di 
Assistenza” that every region should give to patients. Mammarian ultrasounds is 
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indicated in people with less than 40 years old due to the different density of 
mammarian tissue in this age population [27]. 
Microcalcifications can be seen in 60% of cancer lesions , however they can be a 
characteristic of benign lesions too[28, 29]. 
Magnetic resonance of the breast is indicated if there is a suspicion of multifocality, 
multicentricy or bilaterality. Special use can be considered in presence of mammarian 
prosthesis and in staging of locally advanced disease. Another indication is to search 
the primary tumor when there is presence of adenopathies with negative 
mammography [30-32]. The MRI is the most sensitive diagnostic exam for the 
mamarian prosthesis. The ductalgalattography is indicated in presence of ductal 
papillomatosis or in presence of nipple secretions. Sentinel node biopsy can be 
performed with the use of limpohoscintigraphy [33]. The negative predictive value 
of hystological exam is over 97%. This exam can avoid axillary dissection in patients 
with not palpable mass.  
The cytological analysis can identify: 
-C1: inadequate specimen. 
-C2: negative specimen.  
-C3: uncertain specimen. 
-C4: suspected specimen; hystological confirmation is mandatory. 
-C5: positive specimen for malignant tumor cells.  
Hystopathological analysis: 
The bioptic sampling can differentiate benign from malignant lesions. 15-30% of 
malignant lesions are in situ carcinoma, especially ductal. In 70-85% of cases there is 
a diagnosis of invasive carcinoma, most of them ductal, then lobular, tubular, 
mucinous and medullary[34].   
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1.6 Staging 
TNM (tumor node metastasis) system is universally accepted for the anatomical 
extension of the disease. It is the principal prognostic factor and is necessary to define 
the therapeutic strategy.  
T: anatomic extension of the primary lesion. This parameter is necessary to define a 
neoadjuvant strategy while the pathological staging after surgery is fundamental to 
define the optimal adjuvant therapy.  
N: the nodal status is one of the most important prognostic parameter. The axillary 
nodes receive more than 85% of the lymphatic drainage from all mammalian 
quadrants, while part of the breast parenchyma drains to internal mammary chain 
nodes. The probability of node involvement depends from primary lesion dimension, 
his histological grade and his biological behavior.  
M: the preferential metastatic sites are bone, lung and liver. Therefore the 
instrumental diagnostic is thorax x-rays, CT and bone scan (especially for stage III 
disease). MRI and PET/CT are used in selected case based on specific symptoms[35, 
36]. 
 
Stage 0   Tis  N0  M0 
Stage 1  T1 <2 cm N0  M0 
Stage 2a  T1  N1(1-3ln) M0 
   T2 >2<5 N0  M0 
   T0  N1  M0 
Stage 2b  T2  N1     M0 
   T3 >5 cm N0  M0 
Stage 3a  T0-2  N2 (4-9 ln) M0 
   T3  N1/N2 M0 
Stage 3b  T4 skin/chest wall N0-2  M0 
Stage 3c  any T N3 (>10 ln) M0 
Stage 4   any T  any  N     M1 
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1.7 Prognostic factors  
  
Anatomic extension of the disease (coded by TNM staging system) 
The presence of distant metastasis is associated to a median survival of two years. In 
the presence of non-metastatic disease the prognosis is conditioned by the nodal 
involvement. More important are nodal metastasis greater than 0,2 cm while 
micrometsatsis are of uncertain prognostic value.  
The 10-years disease free survival is 70-80%, it drops down to 20-30% with 1-3 
positive nodes, 10-15% with more than 10 nodes positive. Invasion of the skin and 
muscles is associated to a bad prognosis as well as inflammatory carcinoma[37]. 
Grade of differentiation 
It is evaluated with Scarff-Bloom system, nuclear characteristics, tubuli formation 
and proliferation index. The 10-year survival is 85% for well-differentiated forms 
(G1), 60% for moderately differentiated form (G2), 15% if poorly differentiated 
forms (G3) [38].  
Hormonal receptors expression  
The positivity for estro-progestinic receptors is associated with a more favorable 
prognosis. It is predictive of response to endocrine therapy. 70% of post-menopausal 
women have a ER-positive tumor.  
 
Her2/neu expression 
Hyper expression of Her2/neu protein, part of EGFR complex, is linked to the 
amplification of the gene localized on chromosome 17 (17q21). The hyperexpression 
of  Her2/neu is present in about 25% of cancers and is associated with bad prognosis. 
It is predictive of Trastuzumab response. The evaluation of the Her2/neu protein 
hyper expression is done with himmunoistochemistry or gene amplification with 
FISH[39, 40]. 
Vascular invasion 
It is associated with bad prognosis.  
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Proliferation index 
High DNA content in tumor cells, evaluated by cytometry, is an index of malignity. It 
is evaluated by the number of cells at S stage of cell cycle or by 
immunihistochemstry with monoclonal antibodies against Ki-67[41].  
Other molecular markers have prognostic value: p53, hystotype: E-caderine e tissue 
inhibitors of metalloproteinase (TIMPs) [39, 40].  
 
1.8 Therapeutic approach  
The therapy for breast cancer is multidisciplinary: surgery, radiotherapy, medical 
therapy, and supportive care.  
 
1.8.1 Surgery and adjuvant therapy 
 
Early breast Cancer 
Surgery is the standard approach.  
Conservative strategies such as nodulectomy, lumpectomy or quadrantectomy have 
the same outcomes of demolitive procedure such as mastectomy[42]. 
Complete nodal dissection including the first two stations, is considered to be the 
standard approach. Sentinel node dissection is indicated for patients with clinically 
negative axillary nodes [43].  
 
Adjuvant radiotherapy 
The radiation field should include the entire residual breast gland. Usually a 
fractioned scheme is adopted with 50 Gy in 25 sessions 5 times a week [44, 45]. 
Radiotherapy on thoracic wall is indicated after mastectomy if the primary tumor 
dimensions are over 5 cm or if more than 4 axillary nodes are interested.  
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Adjuvant medical treatment 
The choice of adjuvant chemotherapy is based on the evaluation of predictive factors 
(hormonal status and Her2/neu expression) and of prognostic factors (anatomic 
extension, grading, vascular invasion, proferation index). 
 
Adjuvant hormonoterapy 
The hormonal treatment is indicated in hormone responsive tumors with more than 
1% of estrogen or progestins receptors. In premenopausal patients the 5 years 
treatment with Tamoxifen plus ovary ablation for 2-5 years is the standard approach. 
Overall, the reduction of the relapse risk and mortality rate is 39% and 31% 
respectively. In postmenopausal women the standard treatment is the administration 
of aromatase inhibitors for 5 years or the alternation with Tamoxifen [46]. 
 
Target therapy 
In patients with Her2+ with T > 1 cm Trastuzumab treatment for one year is a 
standard approach. Trastuzumab is an monoclonal antibody directed against the 
extracellular domain of HER-2/neu receptor. Trastuzumab inhibits the  tirosin-kinasic 
activity of Her2, favoring the apoptosis of the cell and the activate the cell mediated 
immunity (ADCC).  Clinical trials have shown a reduction in relative risk of relapse 
of 50%.  
 
1.8.2 Therapy of advanced disease 
The objective is to prolong survival and to maintain a good quality of life. The 
systemic treatment is the treatment of choice. Again the treatment should take into 
account the presence of predictive and prognostic elements.  
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2. METASTASIS, MMPs, ADAMs and ADAMTSs 
 
2.1 Metastatic phenotype 
The proteolysis, the motility and the cellular adhesion are considered the most 
important elements for the cancer cell to metastasize. These functions are regulated 
by some proteins that send signals to the cellular and extracellular compartment of 
the host. Cytokines, motility factors, receptors, enzymes regulate the cross-talk 
between signals. The extracellular matrix (ECM) can be remodeled and favor the 
invasion.  
I. Adhesion. The first step of the metastatic process is the separation from the 
primary tumor. The cadherin-E is a molecule that mediates the cell-cell adhesion in 
epithelial tumors. The loss or reduction of cadherin-E is associated with an advanced 
stage of disease. The extracellular part of this molecule is responsible of the 
homotypic interaction within cells.  
The adhesion to surface glycoproteins of the extracellular matrix (ECM) is mediated 
by receptors. Among these, the integrines are a big family of hetrodimeric receptors 
(about 24) composed of two subunits, α  e β. The characteristic of these molecules is 
that the same ligand can bind more than one integrin and the same receptor can bound 
more than one ligand. The reduced expression of the integrines α1, α6, β1, β4 is 
involved in the loss of adhesion to the matrix, favoring the metastatization process of 
melanoma, colorectal cancer, breast and lung cancer. On the other side the hyper 
expression of the integrin α4β1 is a bad prognostic index for cutaneous melanoma. 
FAK (focal adhesion kinase), whose phosphorylation is necessary for the migration 
signals, links the signal mediated by integrins with Ras-Raf e MAPK-ERK. It is 
described as bi-directional cross-talk and redundancy between signals with the 
increase in proliferation, survival and motility (outside-in signaling); these effects can 
influence, on the return, the expression of surface molecules (inside-out signaling).   
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Many other heterotypic cell-cell interaction are involved in the metastatic process. 
These include adhesion molecules (CAM), as ICAM  (intracellular adhesion 
molecules), whose ligand is the integrin  β2 expressed on the circulant leukocytes;  
VCAM (vascular cell adhesion molecules) the ligand for cells expressing α4β1, and 
NCAM (neural cell adhesion molecules). The selectins L, E, P link one carbohydrate 
and sialyl-Lewis-x, sialyl-Lewis-a present on carcinoma cells.  
II. Degradation and invasion.  The proteolytic modification of the extracellular 
matrix is an essential component for the tumoral invasion.  
The main enzymes degradating the ECM in tumors are a) the matrix 
metalloproteinases (MMP); b) the lisin-ADAM; c) the serin-proteinases as the 
plasminogen activator and plasmin: d) the cistein-proteases with catepsine; e) the 
heparanase. The main substrates of the ECM are type I and III collagens localized in 
the  stromal and type IV and V collagens localized on the basal membrane [47]. 
 
Every matastatization process can be summarized in the following events: interaction 
between tumoral and stromal cells; interaction with the ECM (process defined 
epithelial-to-mesenchymal transition); neovascularization and escape from apoptosis.  
These process requires the matrix metalloproteinase action[48]. In the bone 
progression the role of metalloproteinases is fundamental because the tumoral 
expression in bone tissue requires the destruction of a particularly abundant and 
resistant matrix.  
 
 
2.2  The bone “recess”. 
Bone metastasis are common in patients affected by advanced breast cancer. In 
patients affected by metastatic breast cancer  (MBC), the bone represents the most 
common site of metastatization [49]. 
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Some elements can explain the high frequency of bone metastasis: the blood flow is 
abundant in the bone marrow, the cancer cells produce adhesion molecules than link 
stromal cells and bone matrix, the bone tissue is a source of growth factors [50].  
The bone recess provides homing signals to cancer cells; The physical (acid pH, high 
extracellular calcium concentration) and biochemicals properties (cytokines, growth 
factors) of the bone create a good micro environment for tumor growth [51].  
The tumor cells express CXCR4 receptors for the chemokine that bound the stromal-
cell derived factor 1 (SDF-1) in the bone environment [52].  
The expression of RANKL in the bone seems to contribute to bone metastasis 
development binding his receptor to tumor cells surface [53]. 
 
2.2.1 Bone metastasis from breast cancer 
Bone metastasis from breast cancer are usually ostheolytic. 
Osteoclasts mediate the bone destruction. Cancer cells produce factors that induce the 
osteoclasts production. Bone matrix releases factors stimulating the tumor growth and 
bone destruction [54]. 
Cancer cells can secrete the PTHrP (parathyroid hormone-related peptide). When 
PTHrP bounds his receptor (PTHR1), on the osteoblasts, stimulates the expression of 
RANKL. RANKL bounds his receptor on the osteoclasts precursors. The osteoclasts 
destroy bone tissue producing growth factors, proteins, IGF-1, TGF-beta. 
 
2.3 Metalloproteinases 
 
Every process of remodelling and repair of tissues require a controlled degradation of 
extracellular matrix (ECM). Cancer, arthritis and cardiovascular disease are 
characterized by a ECM remodelling generally in a pathological [55]. The main 
enzimatic group involved in the degradation of ECM is the superfamily of the 
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metalloproteinases Zinc-dependent, that includes the matrix metalloproteinases 
(MMPs), also known as matrixines, the ADAMs and the ADAMTSs. 
The MMPs are zinc-metalloproteasese multidomains, and the sequence homology 
with the catalytic domain of the collagenases of fibroblasts (Collagenase 1) or MMP-
1 is a major criterion to belong to the family. 
The metalloproteinases are able to degrade all ECM components, to release and 
activate/inactivate a great number of cellular functions. The MEROPS database 
classifies the MMPs as a subfamily of the metzincines (M10). The catalytic domain 
contains the bound site Zn2+ HEXXHXXGXXH and a methionine, to make a “met-
turn” of eight remains, that sustains the pocket structure of the active site around the 
Zn2+ catalytic.  
The MMPs are synthesized as pre-proenzimes, which have the “cistein switch” 
PRCGXPD motif, where the cysteine residue maintains the proMMPs inactive.  
The MMPs are classified as: collagenase, gelatinase, stromelisine, matrilisine, 
membrane-type (MT)-MMPs.  
Usually the MMPs are composed of a pro-peptide of about 80 amino acids, a catalytic 
domain of 170 amino acids, a link peptide (“hinge region”) and a hemopexinic 
domain of 200 amino acids. The only exceptions are the MMP-7 (matrilisine 1), 
MMP-26 (Matrilisine 2) and MMP-23 that lack of the link peptide and the 
“hemopexin-like” domain[56]. 
 
2.3.1 Collagenases 
This group is composed of three proteins: collagenase 1 (MMP-1), collagenase 2 
(MMP-8) e collagenase 3 (MMP-13). They have three domains: propetidic, catalytic 
and hemopexin-like. Their function is to degrade the fibrillar collagen type I, II, III in 
¾ and ¼ fragments.  
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2.3.2 Gelatinases 
Gelatinase A (MMP-2) and Gelatinase B (MMP-9) belong to this group. They can 
degrade the denaturated collagen, gelatins, native collagen type IV, V e XI, laminine. 
MMP-2 (in contrast to MMP-9) can degrade native collagen type I ,II, III as 
collagenases. The collagenolytic activity of MMP-2, in solution, is weaker than the 
MMP-1 one or other collagenases.  
 
2.3.3 Stromelisines 
MMP-3 (stromelisine 1), MMP-10 (stromelisine 2), MMP-11 (stromelisine 3) has teh 
same domain organization of the collagenases but they don’t clivate the interstitial 
collagen. MMP-3 and MMP-10, degrade great number of ECM proteins and 
participate to the activation of proMMPs. MMP-3 e MMP-10 are secreted by cells as  
inactive proMMPs, MMP-11 that is activated in the intracellular compartment.  
 
2.3.4 Matrilisines 
This group includes MMP-7 e MMP-26. They don’t have the hemopexin domain. 
MMP-7 is synthetized by epithelial cells and secreted from the apical part of the cell. 
It degrades ECM components but also cellular membrane molecules as Fas-ligand, 
proTNFα, syndecan1 and E-caderin to generate soluble forms. MMP-26 is expressed 
by normal cells as endometrial ones and by carcinomatous cells, it degrades ECM 
components. 
 
 
2.3.5 Membrane-bound MMPs (MT-MMPs) 
There are two types: transmembrane proteins type I (MMP-14, MMP-15, -16 e -24) 
and proteins bounded to glucosilphosfatidilinositol goups (MMP-17 and -25). They 
are activated in intracellular environment; the enzymes are expressed at the 
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membrane. All MT-MMPs, except MMP-17, can activate proMMP-2. MMP-14 can 
activate proMMP-13 on cellular surface. MMP-14 has an intrinsic collagen lytic 
activity, on collagen type I, II, III.  
 
2.3.6  MMP-1 
MMP-1 (Collagenase 1), member of the collagenases family (together with MMP-8 
and MMP-13), is composed by 3 domains: pro-peptidic, catalytic and hemopexinic. It 
has the function to clivate fibrillar collagen type I, II, III. Hyperexpression of MMP-1 
is found in many tumors [57, 58]and is correlated to a more advanced stage of 
disease. Several series show how the expression of MMP-1 is linked to the tumor 
progression ver for his proteolytic activity on protein G bounded to the receptor 
PAR1 (Boire et al. 2005). Murray et al. Have found an high expression of MMP-1 in 
bad prognosis colorectal cancer [59]. Weak expression of MMP-1 correlates with a 
better prognosis in patients affected by advanced colorectal cancer [60]. 
Xin Lu et al. Have shown that MMP-1 and ADAMTS-1 increase the invasivity 
through the ECM and endothelium, and favors the colonization of the bone 
microenvironment  thorough pro osteolytic signals cascade that involve cancer cells, 
osteoblasts and osteoclasts. ADAMTS-1 and MMP-1 help the release of EGF-like 
ligands as AREG, HB-EGF, and TGF-alfa [61]. 
 
2.3.7 MMP-13 
MMP-13 belongs, together with MMP-1 and MMP-8, to collagenase family. 
Constituted by three domains: pro peptidic, catalytic and hemopexin-like; it acts 
degrading mainly fibrillar collagen type I, II e III. The expression of MMP-13 has 
been associated to worse prognosis in colorectal cancer [61] and breast cancer [62] 
and is involved in the cell proliferation in melanoma[63]. 
In non small cell lung cancer, the cell clones that express MMP-13 have the potential 
to spread to teh bone marrow[64]. 
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Cancer cells adherent to the type I collagen act through the signal cascade integrin-
FAK-p38-MAPK to induce MMP-13 and increase the osteolytic activity[65]. The 
breast cancer cell line MDA-MB-232 can destroy bone tissue producing MMP-13, 
with the help of PTHrP[66]. In a murine-based experiment, the hyper expression of 
MMP-13 at the interface Tumor-Bone produce an increased osteolytic activity 
mediated by MMP-9 and TGF-beta activation[67]. 
 
2.4 Inhibitors of metalloproteinases 
 
2.4.1 Endogen inhibitors of MMPs 
They are the α-macroglobulin and the Tissue Inhibitors of MMPS (TIMPs).  The 
human α-macroglobulin is a glycoprotein of 725 kDa composed of four subunits of 
180 kDa. It acts as aspecific protease inhibitor and it is found in blood and interstitial 
liquids. Most of endopeptidases is inhibited by the macroglobulin. The TIMPs are 
four, TIMP-1, -2, -3, -4 of about 22-24 kDs.  TIMP-1 and -3 are glycoproteins, 
TIMP-2 and -4 don’t contain carbohydrates. TIMP-1 is a weak inhibitor of MT1-
MMP, MT3-MMP, MT5-MMP and MT-9-MMP. TIMPs are able to inhibit a large 
spectrum of metalloproteinases. TIMP-1 inhibits ADAM10, while TIMP-2 inhibits 
ADAM12. TIMP-3 has the broadest spectrum of action, including ADAM-10, -12, -
17 and the ADAMTSs subgroup. The suppression of TIMP-3 in mice causes lung 
damage and apoptosis of the mammalian epithelial cells [68]. 
All the TIMPs  have homology and are composed of 184-194 amino acids with 12 
cysteinic remains. The inhibition of MMPs is mediated by N-terminal domain. The 4 
N-terminal Cys1-Thr-Cys-Val4 remains bounded to Glu67-Ser-Val-Cys70 remains 
integrate in the active site of MMPs to chelate Zinc ion. 
TIMP-1 and TIMP-2 promotes the cell growth and protect cells from apoptosis; 
TIMP-3 causes apoptosis of cancer and smooth muscle cells TIMP-3 can bound to 
VEGFR2 and  inhibit the angiogenesis.  
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2.4.2 Synthetic inhibitors of MMPs 
The development of synthetic inhibitors of MMPs was based on the use of known 
peptidic, however thy have a low selectivity. Most of clinical trials with MMPs 
inhibitors were conducted on oncological patients without any clinically relevant 
effect[69, 70]. New variants of inhibitors seem to be more specific and are under 
evaluation. Thyolic, hyidrossipironic and barbituric inhibitors are under study. 
Innovative approaches include the synthesis of antibodies fragments specific for 
catalytic sites of MMPs, the inhibition of intracellular signals to down regulate 
MMPs (id the MAPK, NFkB, AP-1 pathways).   
 
2.4.3 TIMP-2 
The family of TIMPs is the principal regulator of the metalloproteinases. TIMP-2, 
discovered in 1989, has several pleiotropic effects. The TIMPs concentration usually 
exceeds the MMPs one in tissue and extracellular fluids, limiting the proteolytic 
activity[71, 72].  
TIMP-2 block selectively he growth of human endothelial cells in vitro when stressed 
by proangiogenic factors as FGF-a and VEGF-a; it can inhibit the signals of tirosin 
kinase receptors independently from the metalloproteinases inhibition. TIMP-2 
mediates the interaction between MMP-2 zimogen and MT1-MMP. At low 
concentrations TIMP-2 activates MMP-2; at higher concentrations, TIMP-2 creates 
stable complexes with MT1-MMP, inhibiting the activation of MMP-2[73, 74]. The 
TIMPs are down regulated or silenced in several cell lines. The hyper expression of 
TIMPs inhibits the development of metastasis from melanoma in experimental 
models. TIMPs have important anti tumoral activity [73]; TIMP-2 inhibits the growth 
of osteolytic bone metastasis from breast cancer cell lines MDA-231. In one series 
the hyper expression of TIMP-2 can protect cancer cells from apoptosis, through the 
activation of inflammatory signals mediated NF-kB[75]. 
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2.4.4 TIMP-3 
 
It has the broader spectrum of activity. It blocks the link between VEGF and 
VEGFR2, inhibiting the angiogenesis[76]. The hyper expression of TIMP-3 induces 
apoptosis in lung cancer cells A549 and AdCMVTIMP-3 (a viral vector), positively 
regulates the expression of p53, FAS-l, TNFR1 and 2. The use of adenovirus to 
transfect cancer cells A549 in nude mice with TIMP-3 induces the growth arrest [77]. 
 
2.5 MMPs and cancer 
 
Many processes as neoplasms, cardiovascular disease, arthritis show a specific 
pattern of MMPs expression. Some animal models were developed to study the role 
of MMPs in the neoplastic progression. The loss of MMP-7 reduce the development 
of tumors in murine models[78, 79], the hyper expression of MMP-3 in the mammary 
gland brings to the spontaneous development of premalignant lesions.  
Some studies have shown the correlation between MMPs expression and disease 
outcome[80, 81]. MMPs promote cancer growth degradating ECM and secreting 
growth factors. MMP-9 makes VEGF available from ECM and clivates collagen type 
IV to generate Tumstatin, an angiogenesis inhibitor. In carcinomas, MMPs are 
associated to the stromal cells and this emphasized the relevance of the 
mocroenvironment[80, 82].  
The standard approach to study the tumorigenesis consists to delete some MMP and 
TIMP genes in murine models. 
Mice knockout for MMP8 develop a significant number of cutaneous papilloma after 
treatment with carcinogens, mice knockout for MMP9 develop high-grade cutaneous 
tumors. High expression of MMP-12 on human squamocellular carcinoma is 
associated with aggressive disease[83].  
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2.6 ADAMs 
 
ADAMs, or a disintegrin and metalloproteinase, are a family of multidomain trans 
membrane proteases Zn2+- dependent, involved in mechanisms of proteolysis and cellular 
adhesion. They are correlated with other enzymes as ADAMTS (ADAM with trombospondin 
domains), the metalloproteinases of the matrix (MMPs) and the snake venom metalloproteinase 
(SVMP). 40 genes were identify in this family, 21 are considered functional in the 
humans[84].  
 
2.6.1 Structure and function of ADAMs 
The ADAMs are trans membrane proteins composed of 8 domains or regions, a 
prodomain, a metalloproteinases domain, a disintegrinic domain and integrins-ligands, a trans 
membrane sequence and an intracellular C-terminal.  
ADAMs functions include cellular adhesion, migration and signaling. Their principal 
substrates are trans membrane proteins as adhesion proteins and precursors of growth factors 
and cytokines. These proteases cut (shedding) and activate the precursors. ADAM10 and 
ADAM17, are able to activate different ligands for the epidermal growth factor 
receptor (EGR). These ligands include also the EGF, the TGF-α, amphireguilina and 
the betacellulin that are involved in the genesis and progression of cancer. In some 
tumors the expression of ADAMs is correlated with the characteristic of the 
disease[84].  
 
 
2.6.2 Shedding of HER 
HER proteins (also called ErbB) belong to the superfamily of tyrosine kinase 
receptors. There are four type of HER: EGFR/ErbB1/HER1, HER2/ErbB2, 
HER3/ErbB3 and HER4/ErbB4. Two members of this family (EGFR and HER2) 
mediate the cell growth, the survival and his migration. The impaired expression of 
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EGFR and HER2 is implicated in the genesis and progression of some tumor types. 
The HER tyrosine kinases are activated by some ligands synthetized as precursors. 
Specific ADAMs activates these precursors. The hyper expression of ADAM8, 
ADAM9, ADAM10, ADAM12, ADAM17 and ADAM19 can release EGF that will 
link to EGFR[84]. 
 
2.6.3 ADAM10 
The hyper expression of ADAM10 promotes the growth of gastric and oral 
carcinoma, while his down regulation reduces the proliferation of cancer cells[85]. 
 
2.6.4 ADAM12 
ADAM12 is expressed in two isoforms, one long, also called Long Form (ADAM12-
L) and in short (ADAM12-S). The hyper expression of the two isoforms of ADAM12 
is increased in the mammalian tumor tissue. 
The hyperextension of the trans membrane isoform ie ADAM12-L, is significantly 
increased in the early stage of breast cancer while both isoforms are hyper expressed 
in advanced disease. An increase in the expression of the trans membrane isoform 
ADAM12-L, in stages I and II of breast cancer, could reflect his role on cancer 
growth through shedding way. ADAM12-S levels are higher in more advanced breast 
cancers. Data from Roy et al. suggest that the increased expression of ADAM12-S, 
favors local tumor invasion, vascular invasion and nodal metastatization. The down 
regulation of ADAM12 could be a potential therapeutic target in breast cancer.	  
ADAM12 has a low expression in most normal tissues while is highly expressed in 
cancer cells in carcinomas in situ (CIS) and invasive di carcinomas [86]. 
Three somatic mutations of ADAM12 were identified in breast cancer, one in the 
metalloproteinasic domain, one in the disintegrinic domain and one in the 
intracellular domain. ADAM12 expressed in cells of breast cancer favors the 
progression of tumor inducing the apoptosis of the stromal cells[87]. Urinary levels 
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of ADAM12 correlate with disease stage in patients affected by breast cancer and 
those levels increase with disease progression[88-90]. ADAM12 degrades some 
molecules of the extracellular matrix including type IV collagen and fibronectin.  
 
2.6.5 ADAM17 
Also called TACE, ADAM17 is hyper expressed in breast, ovarian, renal, prostatic 
and colorectal carcinoma. Treating cell lines of breast cancer with antibodies anti-
ADAM17 diminish cell proliferation [91]. 
High levels of ADAM17 are predictive of bad outcome inpatients affected by breast 
cancer and highest levels were found in high grade (G3) tumors[92].   
 
2.7 ADAMs and cancer 
 
ADAMs can promote the cancer growth. One of the mechanisms is he release of 
growth factors that stimulates the cell progression and growth. The most studied 
factor activated by ADAMs are ligands family of EGFR/HER. The activated form of 
these ligands bounds to one or more receptors of the EGFR/HER family [93]. When 
activated, these receptors start a cascade of events that stimulate the proliferation, the 
motility and cell survival. There are correlations between ADAM-mediated release of 
growth factors, signalling EGFR mediated and proliferation or migration of 
malignant cancer cells. Treating murine embryonic fibroblasts with the platelet 
derived growth factor receptor beta increase the activation of ADAM17, the release 
of EGFR ligands, to the EGFR signaling [94].	  
In tumor lung tissue the hyper expression of ADAM28 seems to correlate with nodal 
metastasis[95]. ADAM9 is significantly increased in patients with breast cancer and 
nodal involvement [96]. 
ADAM17 levels can be an independent predictive factor of outcome [97]. 
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2.8 ADAMTSs 
 
ADAMTSs (a disintegrine and metalloproeinase with trombospondin motif) is a group of 20 
metalloproteinasi correlated to ADAMs proteinases. ADAMTSs are secreted molecules[98]. 
Some ADAMTSs (ie ADAMTSs-1, 4 and 9) can bind to the ECM, with the mediation of 
central domain and the C-terminal[99].  
 
2.8.1 ADAMTS1 
ADAMTS1 promotes the development of lung metastasis in murine breast cancers through an 
increased proliferation, survival and tumor invasion. ADAMTS1 seems to favor cancer 
angiogenesis and is overexpressed in metastatic breast cancer [100]. 
Silencing ADAMTS1 and MMP1 dramatically reduces bone metastasis in animal. On the 
contrary, the hyper expression of ADAMTS1 and MMP1 increases the number of bone 
metastasis and osteolytic events[101]. 
ADAMTS-1 e ADAMTS-8 can inhibit angiogenesis VEGF induced[102].  
 
3. OBJECTIVES OF THE STUDY  
 
This mono institutional study evaluates the expression of a panel of biological and 
molecular markers in two cohorts of patients with breast cancers affected or not 
affected by bone metastasis. 
The main end point is to verify if there is some marker significantly correlated with 
the risk of bine metastatization.  
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4. MATERIALS AND METHODS 
 
4.1 Population 
 
297 records of breast cancer patients (ductal, lobular, mucinous, papillary, tubular, 
apocrine) operated between 1985 and 2001 at San Paolo Hospital in Milan were 
analyzed; formalin fixed and paraffin included tissues were available. Only patients 
with at least 10 years of follow up were considered.  
 
4.2 Tissue Microarray 
 
All avaible slides were revised, stained with hematossilin and eosin, Tissue 
Microarray (TMA) was created with Tissue Arrayer Minicore instrument (Alphelys, 
Plaisir FR). 
The TMA is a small block of paraffin composed by several tissue samples (cores) 
taken from a “donator” and put in a small block called “acceptor”. 
This technique allows analyzing several tissue samples simultaneously. 
1 mm “cores” were extract, n. 4 of the invasive neoplasia to represent his 
heterogeneity, n.1 of in situ neoplasia and n. 1 of nodal metastasis. 
The “cores” were included in the small block “recipient” at 0,5 mm distance on from 
the other, disposed in 6 “cores” lines per patients (3 patients every line), with a 
overall number of 11 lines. In one “recipient” block were analyzed 33 patients 
contemporarily. 
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4.3 Immunohistochemistry 
 
The block were cut by a micrtome in 3-micron section and stained. 
The immunohistochemstry (IIC) is a tecnique that allow identifying cellular antigens 
on the normal and pathological tissues. It is based on the specificity between antign 
and antibody.  
In our series, we used antibodies directed against classical markers in breast cancer 
(estrogen receptors, clone 1D5; progesteron receptors, clone 636; ki-67, clone MIB-
1; Her-2; Dako, Glostrup Denmark) and antibodies against: 
- MMP1 (clone EP1247Y, diluizione 1:300; Epitomics, Inc., Burlingame CA, USA) 
- MMP13 (clone M66, diluizione 1:50; Santa Cruz Biotechnology, Inc., Santa Cruz 
CA, USA) 
- TIMP2 (clone 3A4, diluizione 1:100; Abcam, Cambridge, UK) 
- TIMP3 (clone 136-13H4, diluizione 1:1000; Abcam, Cambridge, UK) 
- ADAM10 (rabbit polyclonal ab 19997) 
- ADAM12 (goat polyclonal ab 28747) 
- ADAM17 (mouse polyclonal ab 57484) 
- ADAMTS1 (rabbit polyclonal ab 28284) 
When required, to ameliorate tissutal immunoreactivity, the sections, before 
incubation with primary antibody, were treated with antigenic unmasking using a 
solution of EDTA at pH 8 (MMP1) or citrate at pH 6 (TIMP3) in a thermostated 
small bath at 97,5°C for 35-40 minutes.  
For the MMP1 antibody a blocking solution was used (Protein Block, Dako,  
Glostrup Denmark, 30 minutes at normal temperature) to make the coloration more 
precise. 
All the immunohistochemics labeling were done with the automatic i6000 BioGenex 
(Menarini Diagnostics, Firenze, It) and visualized with the revelation system 
NovoLink Polymer (Novocastra, Newcastle Upon Tyne, UK). 
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For all studied antibodies the presence or absence of immunoreactivity was 
evaluated, both in citoplasmatic and at membrane surface site. A score from 0 to 3 
were used, as follows: 0= none immunoreactivity; 1= weak immunoreactivity; 2= 
moderate immunoreactivity; 3= intense immunoreactivity. A positive expression was 
defined as the presence of 1+, 2+ o 3+ score at immunohistochemistry [103] 
The preparations were examined with a microscope LEICA DMLS (Leica 
Microsystems, CMS GmbH, Wetzler, Germany). 
 
4.4 Statistical analysis 
Descriptive statistics were computed to show the clinical and biological 
characteristics of the patients.  
The antibody status, the receptors positivity and Her2/neu status were codified in 
dichotomic variables.  
The variables were first tested with a univariate analysis, with a statistical 
significativity for p<0.10, to evaluate the independent impact of variables on bone 
metastatzation. For those variables resulted significant at univariate analysis, a 
multivariable analysis were computed with a statistical significance for p<0.05. 
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5. RESULTS 
A summary of the clinic-pathological features of the patients in the control group and 
those in the group with bone metastasis is shown in the table 1.  
 
Table 1 - Demographic features and tumor characteristics of the sample 
Variable Bone metastases No bone metastases 
 
Overall 
 
Number of women – N (%) 207 (69.7) 90 (30.3) 297 (100) 
Median age [min-max]– years 
Missing values 
62.5 [27-84] 
0 
62 [28-89] 
1 
61 [27-89] 
2 
Histology – N (%) 
CDI 
CDL 
Mixed 
 
74 (30.0) 
10 (28.6) 
6 (40.0) 
 
173 (70.0) 
25 (71.4) 
9 (60.0) 
 
247 (83.2) 
35 (11.8) 
15 (5.0) 
Grade – N (%) 
1 
2 
3 
 
11 (26.2) 
41 (25.5) 
38 (40.4) 
 
31 (73.8) 
120 (74.5) 
56 (59.6) 
 
42 (14.1) 
161 (54.2) 
94 (31.6) 
ER – N (%) 
Negative 
Positive 
Missing 
 
17 (40.5) 
73 (28.7) 
. 
 
25 (59.5) 
181 (71.3) 
1 
 
42 (14.2) 
254 (85.8) 
1 
PgR – N (%) 
Negative 
Positive 
 
31 (36.5) 
59 (27.8) 
 
54 (65.5) 
153 (72.7) 
 
85 (28.6) 
212 (71.4) 
C-erb – N (%) 
0 
1 
2 
3 
 
30 (30.3) 
21 (28.8) 
15 (26.8) 
24 (35.3) 
 
69 (69.7) 
53 (71.2) 
41 (73.2) 
44 (64.7) 
 
99 (33.3) 
74 (24.6) 
56 (18.9) 
68 (22.9) 
Metastasis other than bone – N (%) 
No 
Yes 
 
45 (17.9) 
45 (97.8) 
 
206 (82.1) 
1 (2.2) 
 
251 (84.5) 
46 (15.5) 
 
Mean age of the population is 61 years (standard deviation 11.7; range 27-89 years). 
The control group has 207 patients (69,7% of the total), which are, after a ten-year 
follow-up, free from disease or at least without bone metastasis. The group with bone 
metastasis consists of 90 patients (31,3% of the total). Of those, 90 patients, 45 (50%) 
have only bone localization of disease while 50% have both visceral and bone 
metastasis. In the control group, 173 patients out of 206 (83,6%) had ductal invasive 
carcinoma, 25 patients (12,1%) had lobular invasive carcinoma while 9 patients 
(4,3%) had other hystotype.  
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In the only bone metastasis group, 74 patients (82,2%) had ductal invasive 
carcinoma, 10 patients (11,1%) had lobular invasive carcinoma while 6 patients 
(6,7%) had other hystotype (in particular: apocrine, metaplastic, papillary 
carcinoma, mucinous carcinoma).  
Grading is similar between groups and grade 2 was the more frequent (120/206 
57.9%) in the control group and (41/90, 45.5%) in the bone metastasis group.  
The hyper expression of Her2 was present in 182 /206 (87,9%) patients of the control 
group and in 73 /90 (81,1%) of the metastatic group. 
The expression of PgR was positive in 153 /90 (73,9%) of patients in the control 
group, and in 59 / 90 (65,5%) of the group with bone metastasis. 
In the control group 138 patients had positivity for Her2 protein (66,6%) and 60 (66,6%) 
were the patients positive for the protein with bone metastasis. Most of thepatients 
received chemotherapy and hormonal treatment: 151/197 (50,8%) received adjuvant 
chemotherapy, 215/297 (72,4%) received endocrine therapy, 220/297 (74,1%) 
received radiotherapy. 
At the moment the analysis was performed 89 metastatic patients (30%) were 
deceased, 21 with bone metastasis only and 37 with other type of metastatic site.  
Table. 2 
Variable Died Alive 
 
Overall 
 
Number of women – N (%) 89 (30.0) 208 (70.0) 297 (100) 
Bone metastases– N (%) 
No 
Yes 
 
30 (30.3) 
21 (28.8) 
 
69 (69.7) 
52 (71.2) 
 
99 (33.3) 
73 (24.6) 
Metastases other than bone– N (%) 
No 
Yes 
 
52 (20.7) 
37 (80.4) 
 
199 (79.3) 
9 (19.6) 
 
251 (84.5) 
46 (15.5) 
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Tab. 3 – Expression of the proteins studied in the tumoral tissue.   
Variable Bone metastases No bone metastases 
 
Overall 
 
Number of women – N (%) 90 (30.3) 207 (69.7) 297 (100) 
Median Ki67 [min-max]  
Q1-Q3 
Missing values 
15 [1-70] 
10-23 
5 
10 [0-70] 
5-20 
12 
10 [0-70] 
7-20 
18 
MMP1 – N (%) 
Negative 
Positive 
 
35 (33.0) 
55 (28.8) 
 
71 (67.0) 
136 (71.2) 
 
106 (35.7) 
191 (64.3) 
MMP13 – N (%) 
Negative 
Positive 
 
24 (27.6) 
66 (31.4) 
 
63 (72.4) 
144 (68.6) 
 
87 (29.3) 
210 (70.7) 
TIMP2-N (%) 
Negative 
Positive 
 
        13 (14.4) 
77 (85.6) 
 
            49 (24.7) 
          158 (76.3) 
 
  62 (21) 
235 (79.1) 
TIMP3 – N (%) 
Negative 
Positive 
Missing value 
 
9 (10) 
81 (32.8) 
0 
 
23 (11.1) 
184 (67.2) 
1 
 
61 (20.6) 
265 (79.4) 
1 
ADAM17 – N (%) 
Negative 
Positive 
 
8 (19.0) 
82 (32.2) 
 
34 (81.0) 
173 (67.8) 
 
42 (14.1) 
255 (85.9) 
ADAM12 – N (%) 
Negative 
Positive 
 
8 (19.0) 
82 (32.2) 
 
34 (81.0) 
173 (67.8) 
 
42 (14.1) 
255 (85.9) 
ADAMTS1 – N (%) 
Negative 
Positive 
 
7 (20.6) 
83 (31.6) 
 
27 (79.4) 
180 (68.4) 
 
34 (11.4) 
263 (88.6) 
ADAM10 – N (%) 
Negative 
Positive 
Missing value 
 
22 (29.7) 
67 (30.3) 
1 
 
52 (70.3) 
154 (69.7) 
1 
 
74 (25.1) 
221 (74.9) 
2 
The percentages in the column “Overall” are calculated having as denominator the total number of patients 
 
In the control group: hyper expression of MMP-1 was present in 136 patients 
(65,7%); MMP-13 is present in 144 patients (69,6%); the positivity for TIMP-2 is 
present in 158 patients  (76,3%); the positivity for TIMP-3 is present in 81 
metastatic patients (90%) and in 184 patients (88,9%); positivity for ADAM17 173 
patients (83,6%); the positivity for ADAM12 is present in 162 patients (78,3%); 
hyper expression of ADAMTS1 is present 180 patients (86,9%); positivity for 
ADAM10 is present in 154 patients  (75,5%). 
In table 4 all variables and their p value are shown. 
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Tab.4 Effect of different parameters on the risk of metastasizing- Univariate and Multivariate                 
Logistic Regression Models 
 
 Univariate  
analysis 
 Multivariate 
analysis 
 
Variable OR (95%CI) p-value OR (95%CI) p-value 
Age (increase of 
10 years)  
1.14 (0.92-1.41) 0.240   
Histology 
Mixed 
CDI 
CDL 
 
1 
0.64 (0.22-1.87) 
0.60 (0.17-2.13) 
 
 
0.415 
0.429 
  
Grade 
1 
2 
3 
 
1 
0.96 (0.44-2.09) 
1.91 (0.86-4.26) 
 
 
0.924 
0.113 
  
Positive ER 
status 
0.59 (0.30-1.16) 0.128   
Positive PgR 
status 
0.67 (0.39-1.15) 0.834   
Positive MMP1 0.82 (0.49-1.37) 0.448   
Positive MMP13 1.20 (0.69-2.09 0.512   
Positive TIMP3 1.12 (0.50-2.54) 0.777   
Positive TIMP2 1.80 (0.92-3.52) 0.086   
ADAM17 2.01 (0.89-4.54) 0.092 1.35 (0.54-3.37) 0.526 
ADAM12 2.85 (1.28-6.32) 0.010 2.59 (1.06-6.29) 0.036 
ADAMTS1 1.78 (0.74-4.25) 0.195   
ADAM10 1.03 (0.58-1.83) 0.924   
 
 
Non-statistically significant differencies were found between the two groups 
regarding cancer hystotype (p value 0.77). Expression of ER, PgR and Her2 is similar 
between the two groups (p 0.13, p 0.14 and 0.83). 
Tumoral grading, MMP1, ADAM 17 and ADAM 12 were the parameters selected by 
the univariate analysis. 
ADAM12 expression was the only parameter significantly different between the two 
groups (78,26% vs 91,11% with p 0.036, OR=2.59, 95%IC 1.06-6.29). 
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6. DISCUSSION 
Our study shows that ADAM 12 is the only hyper expressed protein in tumoral tissue 
that is significant related with bone matastatization. 
Our results are discordant with those of Narita et al.[104], Where there was not a 
correlation between ADAM 12 and bone metastasis. In the studies previously 
mentioned the population analyzed had an inadequate sample (38 and 92 patients). 
In a recent study of Roy et al. [105]ADAM12 induces estrogen-resistance in hormone 
sensitive tumors. Cancer cells hormone sensitive and expressing ADAM12, when put 
in a medium with low estrogen levels, became resistant to the hormonal treatment 
growing faster than cancer cells not hyper expressing ADAM12. It can be 
hypothetized that ADAM12 play a role as mediator of the resistance to the hormonal 
treatment, for example the EGFR way. Targeting ADAM12, together with hormonal 
treatment, could be a new approach to overcome anti estrogenic resistance.   
Among metastatic patients, 73,3% had a ER-positive and ADAM12-positive disease. 
According to Roy et al. results, it can be hypothesized that some ormonosensitive 
patients, treated with hormones would develop bone metastatization due to 
hyperexpression of ADAM12. This subgroup of patients ADAM12 and ER-positive, 
an have developed ormonoresistant disease during hormonal treatment. 
In conclusion, in our series, in the subgroup analysis of patients with ≥ 65 years no 
variable has been associated with bonemetastatization. A possible explanation of that 
result could be a low ADAM12 hyperexpression in older population as found in other 
literature series (Narita et al., where ADAM12 is significantly hyperexpressed in 
women with less than 50 years than in older women[104]. In particular, the pre or 
post meopausal status could bring to different proteolytic cascades.  
Our results are concordant with those of Sjoblom et al. [106] in the analysis of the 
breast cancer genome. They have highlighted ADAM12 as candidate gene cancer; in 
the 122 genes most frequntly mutated in breast carcinoma, the only gene coding for 
one ADAMs,  was the one coding for ADAM12.  
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Most of knowledge on MMPs and ADAMs comes from studies on animal models or 
cell cultures. 
Syntetic inhibitors of MMPs and ADAMs tested in phase II and III studies have 
shown moderate activity[69, 70]. 
Even if our study showed the correlation between ADAM12 and bone metastasis, 
there is the need of further studies to establish the exact relationship between 
thisprotein and bone disease. ADAM12 can however be tested as a possible target of 
anticancer treatment. 
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